aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
10 August 2017 - 10:45PM
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of Physiocrine-based therapeutics
to address severe, rare diseases, will report its financial results
for the second quarter 2017 after the U.S. financial markets close
on Monday, August 14, 2017.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development
of innovative medicines for patients suffering from severe, rare
diseases using its knowledge of Physiocrine biology, a newly
discovered set of physiological pathways. To date, the Company has
generated three innovative therapeutic candidate programs based on
its knowledge of Physiocrine biology in three different therapeutic
areas. aTyr has built an intellectual property estate, to protect
its pipeline, comprising over 220 issued patents or allowed patent
applications that are owned or exclusively licensed, including over
300 potential Physiocrine-based protein compositions. aTyr's key
programs are currently focused on severe diseases characterized by
immune imbalance for which there are currently limited or no
treatment options. For more information, please visit
http://www.atyrpharma.com.
Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2024 to May 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From May 2023 to May 2024